Related Experiment Video
Updated: May 8, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Prostate-specific antigen and prostate cancer mortality: a systematic review
Lauren P Wallner1, Steven J Jacobsen
1Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA. Lauren.P.Wallner@kp.org
American Journal of Preventive Medicine
|August 20, 2013
Summary
Prostate-specific antigen (PSA) screening may reduce prostate cancer mortality, but evidence is limited. Case-control studies suggest a benefit, yet potential biases necessitate cautious interpretation and further research for definitive conclusions.
Area of Science:
- Oncology
- Preventive Medicine
- Biostatistics
Background:
- Current evidence on prostate-specific antigen (PSA) screening for prostate cancer remains debated.
- Despite some clinical trials and reviews indicating limited mortality benefit, confusion persists regarding PSA's utility.
- The U.S. Preventive Services Task Force has provided guidance suggesting minimal benefit from PSA screening.
Purpose of the Study:
- To systematically review case-control studies evaluating the association between PSA screening and prostate cancer mortality.
- To synthesize findings, assess limitations, and identify future research directions.
- To address the ongoing uncertainty surrounding PSA screening effectiveness.
Main Methods:
- A systematic literature review was conducted in 2012.
- Identified case-control studies published within the last 20 years.
- Focused on studies examining the link between screening and prostate cancer mortality.
Main Results:
- Seven case-control studies were identified.
- The majority of studies indicated a reduction in prostate cancer mortality with PSA screening.
- Potential biases (selection, exposure measurement, lead/length time, digital rectal examination influence) may limit findings.
Conclusions:
- Existing case-control studies suggest a mortality benefit from PSA screening.
- Findings must be interpreted cautiously due to inherent biases in case-control study designs.
- Future research should directly address identified biases to clarify the association between PSA screening and prostate cancer mortality.
Related Concept Videos
01:20Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...